Search jobs U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review
Application for Orally Administered Selective P2X3 Receptor Antagonist Based on Findings from Two Phase 3 Trials in Patients with Refractory or Unexplained Chronic Cough
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for gefapixant, an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults. This application for gefapixant will be discussed at an upcoming advisory committee meeting. No date has been set yet. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action date, of Dec. 21, 2021.
U S FDA Accepts Merck s Gefapixant New Drug Application for Review investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
The MEP Lung Health Group: Raising awareness of respiratory diseases across Europe
The group, launched last October, aims to stimulate debate and raise awareness of the risk factors and the complications of respiratory diseases, explains co-chair Željana Zovko.
Adobe stock
01 Mar 2021
The COVID-19 pandemic has shown EU Member States what the Union can achieve with an enhanced and coordinated response. This momentum should now be used to transpose the lessons learned to other health-related issues and to develop long-term strategies.
Before the pandemic, Europe registered over 600,000 deaths a year due to respiratory diseases, while lung cancer is the third-most common type of newly diagnosed cancer on our continent. Both COVID-related and non COVID-related health problems need greater attention, improved monitoring and actions to enhance prevention and treatment.
What to consider while exercising during the COVID-19 pandemic to stay safe and healthy ballstatedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ballstatedaily.com Daily Mail and Mail on Sunday newspapers.
Binah.ai Appoints Dr. Naveh Tov as Chief Medical Officer
Share Article
Dr. Tov’s new role serves as another step in Binah.ai’s journey to improve healthcare access
We are delighted to welcome Dr. Tov to the Binah.ai family, and value his input greatly as a professional with a vast amount of experience in both medicine and technology TEL AVIV, Israel (PRWEB) February 24, 2021 Binah.ai, a leading provider of general health and wellness video-based monitoring tools powered by artificial intelligence (AI), today announced Dr. Naveh Tov, M.D., Ph.D., as its Chief Medical Officer, effective immediately. Dr. Tov will join Binah.ai’s growing leadership team, providing expert medical guidance for the company’s strategic vision to become a global leader as a software-as-a-medical-device (SaMD) solution provider, disrupting the remote patient monitoring industry.